Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Pharma Mar Ord Shs PHMMF

Healthcare Biotechnology
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (PINL:PHMMF)

Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants

PR Newswire January 11, 2022

PharmaMar Announces the U.S. FDA Approval of lurbinectedin (Zepzelca(TM)) for the Treatment of Metastatic Small Cell Lung Cancer

PR Newswire June 16, 2020

PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin® (Plitidepsin) for the Treatment of Patients With COVID-19

PR Newswire April 28, 2020

Sylentis, PharmaMar Group, Announces the End of Patient Recruitment for its HELIX Trial

PR Newswire October 19, 2018

PharmaMar Presents the Overall Survival Data From the Phase I/II Study of lurbinectedin in Combination With Doxorubicin for Relapsed Small Cell Lung Cancer

PR Newswire September 24, 2018

PharmaMar is Announcing its Intention to Conduct a Registered Public Offering of American Depositary Shares

PR Newswire September 7, 2018

PharmaMar Will Present the Results of the Phase I/II Study With Lurbinectedin in Combination With Doxorubicin in Relapsed Small-cell Lung Cancer During the IASLC World Conference

PR Newswire September 6, 2018

The U.S. Food and Drug Administration (FDA) Has Granted Orphan Drug Designation to PharmaMar's Lurbinectedin

PR Newswire August 3, 2018

PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment

Stockhouse Editorial July 31, 2018
View More News ››

Opinion & Analysis (PINL:PHMMF)

No current opinion is available.
View More Opinion ››

Bullboard Posts (PINL:PHMMF)

Be the first to post on this bullboard.

Koryx Copper Inc.

Koryx Copper Inc.

Koryx Copper Inc. a Canada-based mineral exploration and development company. The Company is in the business of exploring and ...
View More »